SINGZYME
Reliable, fast and flexible technology for developing a wide range of Bio-conjugates
About Us
Our Mission
Singzyme’s mission is to deliver on the promise of effective immuno-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide.
Backed by our first-in-class bioconjugation platform, we support the global pharmaceutical industries with their Research and Development (R&D) endeavours to allow promising therapeutics to reach the patient bedside as fast as possible at the best cost.
Innovative Technology
The core technology of the platform lies in the use of Peptide Asparaginyl Ligases (PALs) to conjugate active drugs or any other payloads to proteins.
Singzyme's platform for antibodies and nanobodies engineering and conjugation provides a one- stop solution to the problems faced by Antibody Drug Conjugates developers, stemming from their manufacturing process. Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.
Applications
- Cancer immunotherapy: faster production of antibody-drug-conjugates with minimal footprint on the final product and the possibility to attach several payloads
- Imaging for disease diagnosis: production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs) with minimal radioactive waste due to the highest conjugation efficiency.